| Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia): An article from: Internal Medicine News | Digitalby Sharon Worcester (Author)
| List Price: | $5.95 | | | Available: | Available for download now |
| | Binding: | Digital | | Publisher: | International Medical News Group | | Page Count: | 2 Pages | | Publication Date: | July 15, 2002 | | Sales Rank: | 6,666,881th |
|
EDITORIAL REVIEWS |
Product Description
This digital document is an article from Internal Medicine News, published by International Medical News Group on July 15, 2002. The length of the article is 497 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia)Author: Sharon WorcesterPublication: Internal Medicine News (Magazine/Journal)Date: July 15, 2002Publisher: International Medical News GroupVolume: 35 Issue: 14 Page: 25(1)Article Type: Product/Service EvaluationDistributed by Thomson Gale |
|
